The study showed NAT2 polymorphisms 803AG are associated with CML protection by a factor of 2.3, (OR = 0.044, 95% CI: 0.020-0.095, p = 0. Here, NAT2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.